Stock DNA
Specialty Chemicals
INR 72 Cr (Micro Cap)
15.00
20
0.00%
0.07
6.54%
1.06
Total Returns (Price + Dividend) 
Latest dividend: 0.1733609958506224 per share ex-dividend date: Sep-20-2017
Risk Adjusted Returns v/s 
Returns Beta
News

Eiko Lifesciences Ltd is Rated Sell by MarketsMOJO
Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 November 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Eiko Lifesciences Ltd is Rated Sell
Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Eiko Lifesciences Ltd is Rated Sell
Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Restructuring
13-Nov-2026 | Source : BSEIn continuation to our earlier announcement dated 05th November 2026. We wish to inform that the Wholly Owned Subsidiary of the Company namely Eiko Scientific Solutions LLP (LLPIN: ACH-4311) has entered into a Joint Venture by forming a Private Limited Company in the name of Oval Eiko Resources Private Limited.
Announcement under Regulation 30 (LODR)-Newspaper Publication
06-Nov-2026 | Source : BSEPlease find enclosed a copy of newspaper publication in the following newspapers dated 06th November 2026 with respect to Unaudited Financial Results (Standalone & Consolidated) of the Company for the Quarter and Half-year ended 30th September 2026 approved at the meeting of Board of Directors held on Thursday 05th November 2026.
Announcement under Regulation 30 (LODR)-Restructuring
05-Nov-2026 | Source : BSEWholly Owned Subsidiary of the Company namely Eiko Scientific Solutions LLP (LLPIN: ACH-4311) is proposed to enter into a Joint Venture Agreement with Oval Projects Engineering Limited for formation of a new Private Limited Company in the name of Oval Eiko Resources Private Limited.
Corporate Actions 
No Upcoming Board Meetings
Eiko Lifesciences Ltd has declared 2% dividend, ex-date: 20 Sep 17
No Splits history available
No Bonus history available
Eiko Lifesciences Ltd has announced 2:3 rights issue, ex-date: 07 Jul 23
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Lenus Finvest Private Limited (17.34%)
2b Black Bio Llp . (9.64%)
41.31%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 51.84% vs 43.01% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 25.00% vs 285.71% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 30.15% vs 117.28% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 201.89% vs 178.95% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period